Skip to main content

Table 2 Univariate and multivariate analyses for overall survival (OS)

From: Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Ā 

Univariate

Multivariate

Parameters

Hazard ratio

P values

Hazard ratio

P values

Ī”S1

1.012 (0.983, 1.042)

0.422

1.015 (0.985, 1.046)

0.329

Ī”S2

0.983 (0.963, 1.004)

0.119

0.981 (0.965, 0.998)

0.026

Ī”V1

0.989 (0.971, 1.007)

0.234

0.995 (0.973, 1.017)

0.648

Ī”V2

0.980 (0.965, 0.995)

0.011

0.976 (0.957, 0.995)

0.012

TTN

0.994 (0.986, 1.003)

0.176

0.997 (0.985, 1.008)

0.574

TTP

1.024 (1.009, 1.039)

0.001

3.155 (2.809, 3.544)

<0.001

RR

0.500 (0.263, 0.950)

0.034

0.597 (0.378, 0.941)

0.026

PR

1.056 (0.857, 1.301)

0.608

1.042 (0.855, 1.270)

0.684

  1. Ī”S1, the percent change in tumor size based on uni-dimensional measurement at the first follow up; Ī”S2, the percent change in tumor size based on uni-dimensional measurement at the second follow up; Ī”V1, the percent change in tumor volume at the first follow up; Ī”V2, the percent change in tumor volume at the second follow up, TTN; time to nadir, TTP; time to progression; RR, response rate, PR; progression rate
  2. Unless otherwise indicated, data in parentheses are 95Ā % confidence intervals
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us